Introduction {#sec1-0300060519828528}
============

At present, percutaneous renal biopsy (PRB) is widely used in clinical diagnosis and treatment of kidney diseases. Despite development of new technique and skills, post-biopsy bleeding is still unable to be completely avoided and thought to be a severe or even life-threatening complication of PRB.^[@bibr1-0300060519828528][@bibr2-0300060519828528][@bibr3-0300060519828528]--[@bibr4-0300060519828528]^ Clinical findings of post-biopsy bleeding include formation of para-renal hematoma, hematuria, and the onset of loin and abdominal pain. Treatment for post-biopsy bleeding includes administration of hemostatic drugs or sometimes surgical repair or renal resection. However, transarterial embolization is the preferred approach for renal injury.^[@bibr5-0300060519828528]^

A few reports have described embolization therapy of post-biopsy bleeding complications.^[@bibr6-0300060519828528],[@bibr7-0300060519828528]^ Most of these reports were small studies with a sample size of 20 to 30 cases. In this study, we report our experience of trans-arterial superselective embolization for treating bleeding complications of PRB and its complex causes of disease with a relatively large number of cases.

Materials and methods {#sec2-0300060519828528}
=====================

General information {#sec3-0300060519828528}
-------------------

From January 2006 to December 2017, 43 patients underwent angiography for post-biopsy bleeding complications following percutaneous biopsy. The initial diagnosis included glomerular disease (n = 17), type II diabetes (n = 5), hypertensive nephropathy (n = 5), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (n = 9), and lupus nephritis (n = 7) ([Table 1](#table1-0300060519828528){ref-type="table"}). All renal biopsies were performed under ultrasound guidance with an 18-gauge needle. The symptoms of bleeding included hematuria (n = 43), back pain (n = 41), and decreased blood pressure (n = 39). Computed tomography (CT) was performed for all of the patients and showed para-renal hematoma in all of them ([Figure 1](#fig1-0300060519828528){ref-type="fig"}). Blood transfusion was performed in 23 patients with hemoglobin levels ≤60 g/L. This study was in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) and approved by the Institutional Review Board of Peking University First Hospital. Informed consent was signed by every patient.

![Computed tomography scan shows a perirenal hematoma after percutaneous renal biopsy.](10.1177_0300060519828528-fig1){#fig1-0300060519828528}

###### 

Clinical data and angiographic data of the patients.

![](10.1177_0300060519828528-table1)

  Sex/age (years)   Pathological type            Symptom               Serum creatinine value (μmol/L)   Hemoglobin value (g/L)   Angiographic manifestation   Embolic agent                                                   
  ----------------- ---------------------------- --------------------- --------------------------------- ------------------------ ---------------------------- --------------- ----- ----- ----------------------------------- ---------------------------
  M/62              Glomerular disease           Back pain/hematuria   324                               335                      321                          72              90    135   Pseudoaneurysm                      Microcoil, gelatin sponge
  M/52              Glomerular disease           Back pain/hematuria   465                               464                      463                          66              87    120   Arteriovenous fistula               Microcoil, gelatin sponge
  M/52              Type II diabetes             Hematuria             389                               377                      375                          84              100   110   Pseudoaneurysm                      Microcoil, gelatin sponge
  M/48              Glomerular disease           Back pain/hematuria   498                               487                      483                          92              120   130   Arteriovenous fistula               Microcoil, gelatin sponge
  F/27              Lupus nephritis              Hematuria             711                               710                      721                          55              88    130   Pseudoaneurysm                      Microcoil, gelatin sponge
  F/59              ANCA-associated vasculitis   Hematuria             432                               434                      410                          62              90    128   Pseudoaneurysm                      Microcoil
  M/50              Glomerular disease           Back pain/hematuria   233                               255                      234                          77              100   139   Contrast media extravasation        Microcoil, gelatin sponge
  F/64              Lupus nephritis              Hematuria             220                               201                      210                          84              105   136   Contrast media extravasation        Microcoil, gelatin sponge
  F/51              ANCA-associated vasculitis   Back pain/hematuria   459                               454                      448                          66              99    126   Arteriovenous fistula               Microcoil
  M/50              Hypertensive nephropathy     Hematuria             127                               110                      118                          69              80    140   AVF, contrast media extravasation   Microcoil, gelatin sponge
  M/51              Glomerular disease           Back pain/hematuria   477                               476                      476                          78              100   132   AVF, contrast media extravasation   Microcoil, gelatin sponge
  F/49              ANCA-associated vasculitis   Hematuria             466                               466                      456                          64              61    89    Contrast media extravasation        Microcoil, gelatin sponge
  M/43              Glomerular disease           Hematuria             322                               321                      333                          90              110   120   AVF, pseudoaneurysm                 Microcoil
  F/22              Lupus nephritis              Hematuria             435                               435                      438                          55              80    90    Contrast media extravasation        Microcoil
  M/72              Glomerular disease           Hematuria/shock       274                               263                      271                          49              78    89    AVF, contrast media extravasation   Microcoil
  F/43              Type II diabetes             Hematuria             728                               723                      710                          67              78    107   Arteriovenous fistula               Microcoil, gelatin sponge
  M/42              Glomerular disease           Back pain/hematuria   322                               321                      355                          80              100   106   Pseudoaneurysm                      Microcoil, gelatin sponge
  F/37              ANCA-associated vasculitis   Back pain/hematuria   222                               240                      240                          70              90    110   AVF, pseudoaneurysm                 Microcoil, gelatin sponge
  M/37              Hypertensive nephropathy     Hematuria             433                               444                      442                          84              100   110   Contrast media extravasation        Microcoil, gelatin sponge
  F/17              ANCA-associated vasculitis   Back pain/hematuria   121                               122                      100                          55              87    100   Pseudoaneurysm                      Microcoil, gelatin sponge
  M/38              Glomerular disease           Back pain/hematuria   588                               589                      587                          72              100   120   Pseudoaneurysm                      Microcoil, gelatin sponge
  M/45              Glomerular disease           Back pain/hematuria   328                               340                      320                          64              89    118   Arteriovenous fistula               Microcoil, gelatin sponge
  F/45              ANCA-associated vasculitis   Back pain/hematuria   432                               433                      422                          78              76    109   Pseudoaneurysm                      Microcoil
  M/64              Type II diabetes             Hematuria             333                               322                      328                          54              87    129   Contrast media extravasation        Microcoil
  F/22              Glomerular disease           Back pain/hematuria   476                               480                      472                          92              121   125   Contrast media extravasation        Microcoil, gelatin sponge
  F/31              ANCA-associated vasculitis   Back pain/hematuria   667                               664                      663                          62              90    109   Arteriovenous fistula               Microcoil
  M/63              Type II diabetes             Back pain/hematuria   432                               410                      422                          62              79    134   AVF, contrast media extravasation   Microcoil, gelatin sponge
  M/52              Glomerular disease           Back pain/hematuria   226                               243                      225                          76              99    124   Contrast media extravasation        Microcoil, gelatin sponge
  F/43              Lupus nephritis              Hematuria             346                               376                      352                          87              101   119   Contrast media extravasation        Microcoil, gelatin sponge
  F/42              Lupus nephritis              Back pain/hematuria   656                               631                      649                          67              98    103   Pseudoaneurysm                      Microcoil, gelatin sponge
  F/42              ANCA-associated vasculitis   Hematuria             555                               555                      547                          73              100   142   Contrast media extravasation        Microcoil
  M/57              Glomerular disease           Back pain/hematuria   341                               329                      339                          68              89    104   Contrast media extravasation        Microcoil
  M/64              Hypertensive nephropathy     Back pain/hematuria   145                               130                      147                          76              87    126   Contrast media extravasation        Microcoil, gelatin sponge
  F/43              Lupus nephritis              Back pain/hematuria   511                               521                      520                          64              79    118   AVF, pseudoaneurysm                 Microcoil
  F/51              Type II diabetes             Back pain/hematuria   280                               276                      282                          99              120   122   Contrast media extravasation        Microcoil, gelatin sponge
  M/54              Glomerular disease           Back pain/hematuria   222                               229                      230                          68              90    99    Pseudoaneurysm                      Microcoil, gelatin sponge
  M/63              Hypertensive nephropathy     Back pain/hematuria   444                               432                      440                          81              90    107   AVF, pseudoaneurysm                 Microcoil
  F/38              Hypertensive nephropathy     Back pain/hematuria   365                               380                      363                          101             112   130   Contrast media extravasation        Microcoil, gelatin sponge
  F/22              Glomerular disease           Back pain/hematuria   654                               666                      653                          57              90    129   Contrast media extravasation        Microcoil, gelatin sponge
  F/18              Lupus nephritis              Back pain/hematuria   333                               321                      329                          55              78    119   Contrast media extravasation        Microcoil, gelatin sponge
  M/31              Glomerular disease           Back pain/hematuria   213                               252                      217                          70              100   126   Arteriovenous fistula               Microcoil
  F/22              ANCA-associated vasculitis   Back pain/hematuria   200                               210                      200                          83              100   110   Arteriovenous fistula               Microcoil, gelatin sponge
  M/36              Glomerular disease           Back pain/hematuria   701                               710                      701                          76              98    135   AVF, contrast media extravasation   Microcoil

M: male; F: female; ANCA: antineutrophil cytoplasmic antibody.

Superselective renal artery embolization {#sec4-0300060519828528}
----------------------------------------

A 5 F pigtail catheter was introduced first and whole descending aorta angiography was performed to determine if there was extravasation of contrast medium from the intercostal arteries or the lumbar arteries. A cobra catheter was then introduced into the ipsilateral renal artery and angiography was performed to evaluate the target vessel. A 2.8 F microcatheter (Asahi Intecc Co. Ltd., Aichi, Japan) was superselectively introduced into the target artery of the bleeding site. Metallic fibred platinum microcoils (Tornado Embolization Microcoil; Cook Medical, Bloomington, IN, USA) were used for all patients. A gelatin sponge was used as supplementary embolization for arteries that could be superselected from normal renal arteries. The endpoint of embolization was total obliteration of the target vessel. After treatment, posterior-anterior and oblique angiography was performed again for evaluating the homeostatic effects.

Follow-up procedure {#sec5-0300060519828528}
-------------------

After the interventional procedure, all of the patients entered a follow-up program with continuous monitoring of vital signs for 24 hours. Relief of symptoms was recorded, and hemoglobin and serum creatinine levels were measured on days 1 and 7 after embolization therapy.

Statistical analysis {#sec6-0300060519828528}
--------------------

The paired t-test was used to analyze differences in mean creatinine and hemoglobin values before and after embolization. Statistical analysis was performed using SPSS version 20 (IBM, Chicago, IL, USA).

Results {#sec7-0300060519828528}
=======

We studied 22 men and 21 women (mean age: 44.5.± 14.0 years, age range: 17--72 years). In the 43 patients, 52 branches of the renal artery were found to have an abnormal appearance. Angiography clearly showed typical signs related to bleeding complications. These findings included a pseudoaneurysm in 10 cases arteriovenous fistula in eight cases, extravasation of contrast media in 16 cases, arteriovenous fistula combined with contrast media extravasation in five cases, and pseudoaneurysm combined with arteriovenous fistula in four cases ([Figure 2](#fig2-0300060519828528){ref-type="fig"}). Embolic material was a microcoil alone or a microcoil followed by a gelatin sponge ([Table 1](#table1-0300060519828528){ref-type="table"}). Successful embolization was achieved in 42 patients by one therapy session and one patient required two therapy sessions. The patient who required two times of embolization was diagnosed with ANCA-associated vasculitis. In 29 patients with severe back pain, symptoms gradually improved 2 to 5 days after embolization. All cases of hematuria disappeared from 2 to 7 days after the operation. One patient with hypovolemic shock recovered immediately with steady vital signs after the embolization treatment. Thirty-one patients with original impaired renal function underwent hemodialysis after the operation.

![Different types of renal hemorrhage. (a) Pseudoaneurysm; (b) contrast media extravasation; (c) arteriovenous fistula; (d) arteriovenous fistula and contrast media extravasation; (e) arteriovenous fistula and pseudoaneurysm.](10.1177_0300060519828528-fig2){#fig2-0300060519828528}

In two patients, there were no abnormalities related to the renal artery. The bleeding site was finally confirmed to be a branch of the lumbar artery and iliolumbar artery by angiography for the lumbar artery ([Figure 3](#fig3-0300060519828528){ref-type="fig"}). These patients were successfully treated by intra-arterial embolization.

![Hemorrhage of the lumbar artery.](10.1177_0300060519828528-fig3){#fig3-0300060519828528}

Mean serum creatinine levels were 397.8 μmol/L before embolization (median: 389.0, range: 121.0--728.0 , standard deviation: 163.7 μmol/L, 95% confidence interval: 347.4--448.1), 398.5 μmol/L 1 day after embolization (median: 380.0, range: 110.0--723.0, standard deviation: 162.4 μmol/L, 95% confidence interval: 348.5--448.5), and 395.6 μmol/L 1 week after embolization (median: 375.0, range: 100.0--721.0, standard deviation: 162.7 μmol/L, 95% confidence interval: 345.6.8--445.7). Mean creatinine values 1 day and 1 week after embolization were not significantly different compared with before embolization (95% confidence interval: −4.9--3.4 and −0.92--5.2, respectively) ([Figure 4a](#fig4-0300060519828528){ref-type="fig"}).

![(a) Differences in mean creatinine values before and 1 day and 1 week after embolization (P = 0.677: day 1 versus day 0; P = 0.369: day 7 versus day 0). (b) Differences in mean hemoglobin values before and 1 day and 1 week after embolization (P \< 0.001: day 1 vs day 0 and day 7 versus day 0). Day 0: the day before embolization; day 1: 1 day after embolization; day 7: 1 week after embolization.](10.1177_0300060519828528-fig4){#fig4-0300060519828528}

Mean hemoglobin values were 72.2 g/L before embolization (median: 70.0, range: 49.0--101.0, standard deviation: 12.6 g/L, 95% confidence interval: 68.3--76.1), 93.4 g/L 1 day after embolization (median: 90.0, range: 61.0--121, standard deviation: 12.5 g/L, 95% confidence interval: 89.5--97.2), and 118.7 g/L 1 week after embolization (median: 120.0, range: 89.0--142.0, standard deviation: 14.1 g/L, 95% confidence interval: 114.4--123.0). Mean hemoglobin values were significantly higher at 1 day and 1 week after embolization compared with before embolization (P \< 0.001, 95% confidence interval: −23.8 to −18.5; P \< 0.001, 95% confidence interval: −51.5 to −41.5, respectively) ([Figure 4b](#fig4-0300060519828528){ref-type="fig"}).

Discussion {#sec8-0300060519828528}
==========

Some studies on post-biopsy bleeding complications that used real-time ultrasound guidance and focused on complications showed that the incidence of complications was 7.5% to 58.6%.^[@bibr8-0300060519828528][@bibr9-0300060519828528]--[@bibr10-0300060519828528]^ In our center, only severe bleeding complications needed to be treated by embolization. The definition of a complication in our center is a large hematoma, decreased blood pressure, and extended hospitalization, similar to other studies.^[@bibr1-0300060519828528],[@bibr2-0300060519828528]^

Because of considerable loss of parenchyma, surgical approaches are no longer the first choice in most circumstances of renal vascular injury.^[@bibr11-0300060519828528]^ Otherwise, there is no need for general anesthesia in interventional therapy. Interventional treatment can locate abnormal blood vessels in a timely manner and achieve occlusion without losing normal renal parenchyma. Therefore, interventional therapy has become the first choice for treatment of iatrogenic renal vascular injury.^[@bibr12-0300060519828528][@bibr13-0300060519828528][@bibr14-0300060519828528]--[@bibr15-0300060519828528]^

Angiographic manifestations of renal vascular injury include pseudoaneurysm, renal arteriovenous fistula, and contrast media extravasation.^[@bibr13-0300060519828528]^ All of these manifestations were found in our study. There were no abnormalities related to the renal artery in one patient. The bleeding site was finally confirmed to be a branch of the lumbar artery and iliolumbar artery in this patient. To the best of our knowledge, lumbar or iliolumbar artery hemorrhage rarely occurs after renal biopsy. Only a few reports have described a similar phenomenon of lumbar artery or iliolumbar artery hemorrhage.^[@bibr16-0300060519828528],[@bibr17-0300060519828528]^

Materials that are used in renal artery embolism, such as microcoils, polyvinyl alcohol (PVA) particles, a gelatin sponge, and tissue glue, are widely recognized, and can be selected according to the type of disease and personal habits. The microcoil is suitable for different diameters of arteries. The cages on the coils are easy to induce thrombosis and achieve complete embolism. Studies have shown that use of coil embolization has little effect on renal function.^[@bibr18-0300060519828528]^ Gelatin sponge particles are large and embolized arteries can be recanalized, and thus this method is relatively safe. Therefore, gelatin sponge particles can be used as a supplementary embolization after coil embolism. PVA particles are small in diameter and are a permanent embolic material. PVA particles should not be used for a separate embolism to prevent them from entering a larger arteriovenous fistula directly.^[@bibr19-0300060519828528]^ Our experience in treating renal artery embolization suggests the following: (1) angiography should be comprehensive and the lumbar or iliolumbar artery should not be neglected if necessary; (2) to define the site of bleeding, multi-angle angiography should be performed; (3) preservation of normal renal parenchyma is important; (4) the dosage of contrast medium should be reduced during the operation to prevent deterioration of renal function.

In our study, successful embolization was achieved in all patients, but one patient experienced two times of embolization. The pathological diagnosis of this patient was ANCA-associated vasculitis. Contrast agent extravasation sign was found in the lower pole of the right kidney in the first angiography. We used a microcoil and gelatin sponge to embolize the target artery and no bleeding signs were observed. The patient developed signs of decreased blood pressure and hemoglobin on the second day. We performed a second angiography and found contrast agent extravasation sign in another artery. We used a microcoil and gelatin sponge to embolize the target artery again. The patient's blood pressure was stable after the operation and the hemoglobin level was improved. The patient did not experience re-bleeding. We considered that the body's self-protection mechanism led to renal artery contraction during bleeding. When the first angiography was performed, vascular damage of one artery was smaller than that in the other arteries and the renal artery was contracted. Therefore, there was no sign of bleeding. After the first angiography, a larger area of vascular damage was blocked. Therefore, blood pressure was increased and the mechanism of vasoconstriction weakened. Signs of bleeding occurred in vascular damage of the smaller artery ([Figure 5](#fig5-0300060519828528){ref-type="fig"}).

![(a) A computed tomography scan shows a hematoma. (b) The hematoma fills the posterior renal space. (c) Contrast media extravasation in the first angiography. (d) Renal angiography after the first embolization. (e) Contrast media extravasation in the second angiography. (f) Renal angiography after the second embolization.](10.1177_0300060519828528-fig5){#fig5-0300060519828528}

Some studies have reported renal function after renal embolization. Loffroy et al.^[@bibr6-0300060519828528]^ documented a stable glomerular filtration rate in six patients after embolization and improvement in four patients. Maleux et al.^[@bibr20-0300060519828528]^ studied 13 patients with vascular lesions in renal allografts and found that renal function improved in nine patients. In our study, 31 patients (serum creatinine level \>300 μmol/L) underwent hemodialysis after the operation because of poor renal function. Serum creatinine levels were not significantly altered before and after embolization. Because our patients had poor initial renal function, we considered that stable renal function was a good result. The patients' hemoglobin values were significantly increased 1 day and 1 week after embolization compared with before embolization. This finding indicated that embolization was safe and effective.

The incidence of complications of renal artery embolization is relatively low. Complications include post-embolization syndrome, infection, and renal dysfunction.^[@bibr21-0300060519828528]^ Post-embolization syndrome is characterized by fever and low back pain. After symptomatic treatment, this condition can be improved without special treatment. Patients with a risk of infection should be provided antibiotic prophylaxis after the operation. Patients with poor renal function should be provided hemodialysis after the operation. In our study, there were no obvious complications in any of the patients and 31 patients with poor renal function received hemodialysis.

Conclusion {#sec9-0300060519828528}
==========

This study shows that superselective renal artery embolization is a safe and effective treatment for post-biopsy bleeding complications. This technique offers maximal preservation of the renal parenchyma and protection of renal function. Other arteries should not be neglected if renal arteriography shows no signs of hemorrhage.

Declaration of conflicting interest {#sec10-0300060519828528}
===================================

The authors declare that there is no conflict of interest.

Funding {#sec11-0300060519828528}
=======

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
